• Zimmer Biomet Holdings recently reported that it will release its upcoming earnings results, with analysts expecting revenue of about US$2.22 billion, reflecting year-on-year growth of 9.9% and an improvement from the 4.3% increase recorded in the same quarter a year earlier.
• An interesting angle is that Zimmer Biomet has missed Wall Street’s revenue estimates only once in the past two years, typically outperforming consensus by an average of 0.7%, which may be influencing how investors interpret these latest expectations.
• We’ll now examine how Zimmer Biomet’s history of typically outperforming revenue estimates shapes the investment narrative around this upcoming earnings release.

AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Zimmer Biomet Holdings' Investment Narrative?

To own Zimmer Biomet, you really need to believe in the long-term demand for orthopedic and surgical devices, and the company’s ability to translate that into steady, if unspectacular, growth. The upcoming earnings release, with analysts looking for about US$2.22 billion in revenue and a solid year-on-year lift, slots neatly into that story but does not radically change it. The short-term catalysts still hinge on whether management can convert recent revenue momentum into improving margins and returns on equity, especially after a period of weaker profitability and share price underperformance. At the same time, a high debt load and questions around pay rising while earnings previously fell remain front of mind. The earnings track record versus expectations may temper some of those concerns, but it does not erase them.

However, one risk around leverage and profitability trends is something investors should not ignore. Zimmer Biomet Holdings' shares have been on the rise but are still potentially undervalued by 48%. Find out what it's worth.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates span roughly US$95 to US$172, highlighting very different views on upside. Set that against recent margin pressure and debt concerns, and it is clear you should compare several perspectives before forming a view on Zimmer Biomet’s prospects.

Explore 4 other fair value estimates on Zimmer Biomet Holdings - why the stock might be worth just $95.00!

Build Your Own Zimmer Biomet Holdings Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zimmer Biomet Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zimmer Biomet Holdings' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.